Abbott's Lingo™ Now on Android™, Expanding Access to Real-Time Glucose Data

Rhea-AI Summary

Abbott (NYSE: ABT) announced Lingo, its over-the-counter continuous glucose monitor and app, is now available on Android, expanding access beyond iOS in the U.S. and U.K.

Lingo is intended for adults 18+ not using insulin and offers real-time glucose data and a daily metric, Lingo Count, to quantify glucose spikes. Abbott reported that reducing Lingo Count over about three months halves time above the healthy range and lowers average glucose by 10%. Real-world data showed protein supplementation days had 15% lower odds of glucose spikes and a 2 mg/dL average glucose reduction ( 18% odds and 3 mg/dL reduction among people with obesity).

Positive

• Platform expansion: Android availability widens market access
• Lingo Count reduction: time above range -50%
• Average glucose improvement: -10% after ~3 months
• Protein supplementation: 15% lower odds of glucose spikes

Negative

• Product intended only for adults 18+ not on insulin
• Availability limited to the U.S. and U.K.

Key Figures

Lingo users forming new habits 95% Share of Lingo members reporting new habits from glucose tracking

Prediabetes prevalence 98 million U.S. adults Adults affected by prediabetes cited in article

Lingo Count improvement 10% lower average glucose After about three months of reduced Lingo Count

Time above healthy range Cut in half For users with elevated glucose reducing Lingo Count over three months

Protein effect on spikes 15% lower odds Odds of glucose spikes on days with logged protein supplement

Protein effect on glucose 2 mg/dL reduction Average glucose change on days with protein supplementation

Protein effect in obesity 18% lower odds Glucose spikes odds reduction among users with obesity

Glucose drop in obesity 3 mg/dL reduction Average glucose change with protein supplements in obesity subgroup

Market Reality Check

$125.08 Last Close

Volume Volume 4,207,541 shares vs 20-day average 6,599,215, indicating lighter trading ahead of this news. low

Technical Shares at $125.08, trading below the $130.88 200-day moving average and 11.44% under the 52-week high.

Peers on Argus

Ahead of this Android CGM launch, ABT was down 0.26%. Key device peers like BSX (-0.54%), SYK (-0.41%), and MDT (-0.73%) also traded lower, while SNN ticked up 0.36%, suggesting a modest, mixed sector tone rather than a clear group move.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 04	Product launch	Positive	+0.1%	Launch of two Ensure Max Protein shakes targeting muscle health trends.
Nov 20	Acquisition deal	Positive	-1.7%	Agreement to acquire Exact Sciences for cash, expanding cancer diagnostics.
Nov 04	Brand partnership	Neutral	+1.6%	Hallmark holiday movie featuring Abbott HeartMates community members.
Oct 15	Earnings results	Positive	-2.9%	Q3 2025 beat with 6.9% sales growth and strong CGM performance.
Sep 24	Earnings call setup	Neutral	-1.5%	Scheduling details for Q3 2025 earnings release and conference call.

Pattern Detected

Recent fundamentally positive events (earnings, major acquisition) have often seen muted or negative next-day price moves, while smaller brand/product launches drew mild gains.

Recent Company History

Over the past few months, Abbott has combined steady financial performance with portfolio expansion. Q3 2025 results on Oct 15 showed higher sales and reaffirmed guidance, yet shares fell 2.87%. The Nov 20 agreement to acquire Exact Sciences for about $21 billion also saw a 1.73% decline. By contrast, consumer- and brand-focused announcements, including the Ensure Max Protein launch on Dec 4, saw slight gains. Today’s Lingo Android expansion extends Abbott’s CGM and metabolic-health ecosystem, following that same consumer health and real-world data narrative.

Market Pulse Summary

This announcement extends Abbott’s Lingo platform to Android users, materially widening access to real‑time glucose insights. The release also highlights real‑world data, including 15%–18% lower odds of glucose spikes and up to 3 mg/dL reductions in average glucose with protein supplements, especially in people with obesity. In context of recent earnings growth and the pending Exact Sciences acquisition, investors may track how Lingo adoption, real‑world outcomes, and integration of metabolic-health offerings contribute to Abbott’s Medical Devices growth trajectory.

Key Terms

biowearable technical

"Lingo, Abbott's first over-the-counter biowearable, expands to Android devices"

A biowearable is a small device worn on or inside the body that continuously monitors health-related signals, such as heart rate, activity levels, or sleep patterns. For investors, biowearables represent a growing industry focused on health tracking and personal wellness, with potential implications for healthcare innovation and consumer markets. Their development and adoption can influence related companies and the broader health technology sector.

continuous glucose monitoring medical

"Continuous glucose monitoring devices help people maintain healthy glucose levels"

Continuous glucose monitoring is a system that tracks blood sugar levels in real-time throughout the day and night. It provides constant updates, similar to a car's dashboard showing speed and fuel level at all times. For investors, advancements in this technology can signal progress in health monitoring devices, which may influence the growth and valuation of companies in the healthcare sector.

continuous glucose monitor medical

"Lingo, an over-the-counter continuous glucose monitor (CGM) and app"

A continuous glucose monitor is a small device worn on the body that constantly tracks blood sugar levels throughout the day and night. It provides real-time data, helping individuals manage conditions like diabetes more effectively. For investors, advancements in this technology can signal growth opportunities in healthcare and medical device markets, reflecting broader trends in health technology innovation.

type 2 diabetes medical

"higher risk for prediabetes, type 2 diabetes and other chronic conditions"

Type 2 diabetes is a chronic condition where the body struggles to control blood sugar levels because it becomes less responsive to insulin, a hormone that helps regulate sugar in the blood. It matters to investors because it can lead to increased healthcare costs, affect workforce productivity, and influence the performance of companies in the healthcare and pharmaceutical sectors. Managing or preventing the condition has significant implications for public health and economic stability.

AI-generated analysis. Not financial advice.

• Lingo, Abbott's first over-the-counter biowearable, expands to Android devices
• Continuous glucose monitoring devices help people maintain healthy glucose levels, which are associated with better metabolic health and lower long-term risk of chronic conditions
• New data from Lingo users highlight how protein supplementation is linked to lower glucose in people who use continuous glucose monitors, especially for people with obesity, a group at higher risk for prediabetes, type 2 diabetes and other chronic conditions

ABBOTT PARK, Ill., Dec. 8, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that Lingo, an over-the-counter continuous glucose monitor (CGM) and app, is now available for Android devices. Already available for Apple iOS devices, this expansion gives millions more people access to real-time glucose data, empowering informed choices that help support better energy, sleep, focus and overall well-being.^{i ii iii}

Lingo is for individuals 18 years of age or older and not on insulin who want to make informed decisions about their health. By showing how food, movement and stress affect glucose in real time, Lingo can help people make small, science-backed adjustments that can lead to measurable improvements in health. Ninety-five percent of Lingo members report developing new habits based on glucose tracking. ^{iv v}

Helping More People Understand their Metabolic Health

Glucose serves as one of the body's primary energy sources, powering essential functions from the brain to the muscles. Despite its vital role, data shows that four out of five Americans do not recognize glucose as an important indicator of overall health.^vi Lingo addresses this gap by making glucose insights more accessible and actionable by helping people understand how their glucose may influence their energy, hunger, mood and more.

"Glucose levels and metabolic health are foundational for overall well-being and chronic disease prevention. The need for more glucose awareness is clear," said Amy McKenzie, Ph.D., head of Medical Affairs for Abbott's Lingo business. "Prediabetes – a condition where glucose is elevated but not yet in the diabetes range – impacts more than 98 million U.S. adults, yet 80% of those affected don't know they have it.^vii With awareness and lifestyle changes, prediabetes can be managed or reversed.^{viii ix} Lingo provides the insight needed to help people understand their glucose patterns in real time, empowering informed choices that support better metabolic health."

Lingo helps people understand how food and other lifestyle factors affect glucose by detecting glucose spikes and quantifying their size with Lingo Count™, a daily metric that shows how much glucose spikes affect the body. Lingo Count adds up the impact of each spike based on how big and how long it lasts, providing an easy way to track and improve metabolic health. When Lingo users with elevated glucose levels – like those seen among people living with prediabetes – reduce their Lingo Count over about three months, their glucose significantly improves – cutting time above healthy range in half and lowering average glucose by 10%.^x

Protein Supplementation Can Support Healthy Glucose

New real-world data from Abbott shows how consuming protein supplements, such as high-protein nutritional drinks, is associated with lower glucose levels.^xi  The effect was even more pronounced among individuals with obesity, a group at higher risk for type 2 diabetes and other chronic conditions.

On days when people logged a protein supplement, they had 15% lower odds of experiencing glucose spikes above the healthy range and an average glucose reduction of 2 mg/dL compared to days without protein supplementation. Among those with obesity, the benefit was greater: 18% lower odds of glucose spikes above the healthy range and a 3 mg/dL reduction in average glucose. Given that past research shows that more time above the healthy glucose range is linked to greater risk of type 2 diabetes^xii, these real-world data suggest that protein supplementation may play an important role in supporting metabolic health.

Flattening glucose curves and keeping them in a healthy range is linked to significant health benefits such as better sleep, mood, energy, food cravings and focus.^{xiii xiv} Elevated glucose levels over time can affect metabolic health and increase the risk of serious conditions like type 2 diabetes^xv, heart disease^xvi  and certain cancers.  

Using a continuous glucose monitor like Lingo can help people see what habits keep glucose in a healthy range. Maintaining healthy glucose over time can support long-term health.

Availability

Lingo is available in the U.S. and the U.K.

The Lingo app is now available for download for Android through the Google Play Store and continues to be available for iOS on the Apple App Store.

You can purchase Lingo at hellolingo.com, Amazon, and in-store and online at Walmart.

Press assets including images and B-roll available here.

About Lingo: 
The Lingo Glucose System is intended for users 18 years and older, not on insulin. It is not intended for diagnosis of diseases, including diabetes. The Lingo program does not guarantee that everyone will achieve the same results as individual responses may vary. Consult your healthcare professional before making changes to your diet or exercise regimen or if you have an eating disorder or a history of eating disorders.

About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries. Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube. 

^v Lingo Member Survey. 845 Lingo members in the U.S. 2024 Nov 15-Dec 16. Data on file, Lingo by Abbott. ALB-02208 Thought Leadership_Demographic Cross Tab_US
^vi Lingo State of Wellness Report.  Ipsos National Survey.  1,031 consumers in the U.S. 2024 Nov 15-17.  Date on file, Lingo by Abbott.
^vii Centers for Disease Control and Prevention | CDC. National Diabetes Statistics Report.  [Accessed 2025 Nov 5] https://www.cdc.gov/diabetes/php/data-research/index.html
^viii Perreault L, et al. Regression from pre-diabetes to normal glucose regulation in the diabetes prevention program. Diabetes Care. 2009 Sep;32(9):1583-8. https://pubmed.ncbi.nlm.nih.gov/19587364/
^ix Katula JA, et al. Effects of a Digital Diabetes Prevention Program: An RCT. Am J Prev Med. 2022;62(4):567-577. https://pubmed.ncbi.nlm.nih.gov/35151522/
^x Wilk A, Krishna R, Wasserman A, Baicy E, McKenzie A. Real-World Glycemic Effects Observed with Non-Prescription Real-Time Continuous Glucose Monitoring. Presented at the Diabetes Technology Meeting, Burlingame, CA; October 28-30, 2025
^xi McKenzie AL, Wilk A, Sharn AR, Williams DR. Protein supplement consumption is associated with less glycemic exposure in real-world data. Presented at Obesity Week, November 5, 2025; Atlanta, GA.
^xii Marco A, et al. Time above range for predicting the development of type 2 diabetes. Front Public Health. 2022 Dec 8;10:1005513. https://pubmed.ncbi.nlm.nih.gov/36568777
^xiii Zahedani AD, et al. Digital health application integrating wearable data and behavioral patterns improves metabolic health. NPJ Digit Med. 2023 Nov 25;6(1):216. doi: 10.1038/s41746-023-00956-y. Erratum in: NPJ Digit Med. 2024 Jan 12;7(1):9. https://pubmed.ncbi.nlm.nih.gov/38001287/
^xiv Perreault L, et al. Regression from pre-diabetes to normal glucose regulation in the diabetes prevention program. Diabetes Care. 2009 Sep;32(9):1583-8. https://pubmed.ncbi.nlm.nih.gov/19587364/
^xv Marco A, et al. Time above range for predicting the development of type 2 diabetes. Front Public Health. 2022 Dec 8;10:1005513. https://pubmed.ncbi.nlm.nih.gov/36568777/
^xvi Coutinho M, et al. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care. 1999 Feb;22(2):233-40. https://pubmed.ncbi.nlm.nih.gov/10333939/

 

View original content:https://www.prnewswire.com/news-releases/abbotts-lingo-now-on-android-expanding-access-to-real-time-glucose-data-302635001.html

SOURCE Abbott

FAQ

When did Abbott (ABT) make Lingo available on Android devices?

Abbott announced Android availability on December 8, 2025.

What users is Lingo (ABT) intended for and who is excluded?

Lingo is for adults 18 years or older and not on insulin.

How much can Lingo improve glucose metrics after about three months?

Abbott reported time above healthy range cut in half and average glucose -10% after ~3 months of reducing Lingo Count.

What did Abbott report about protein supplements and glucose for Lingo users?

On days with logged protein supplements, users had 15% lower odds of glucose spikes and an average glucose reduction of 2 mg/dL.

Are the protein supplement benefits different for people with obesity according to Abbott?

Yes—among people with obesity the report showed 18% lower odds of spikes and a 3 mg/dL average glucose reduction.

Where can consumers buy Lingo (ABT) and download the app?

Lingo is sold at hellolingo.com, Amazon, and Walmart; the app is available on the Google Play Store and Apple App Store.